Skip to main content
Jeffrey Humphrey, MD, Oncology, Milton, MA

JeffreyStevenHumphreyMD

Oncology • Milton, MA

Co-Founder, CEO of Charged Biotherapeutics

Join to view full profile

Dr. Humphrey is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Humphrey's full profile

Already have an account?

  • Office

    320 Adams Street
    Milton, MA 02186
    Phone+1 203-927-8307

Summary

  • Jeffrey Humphrey, MD is a healthcare professional based in Milton, MA who specializes in Oncology. He completed his residency at Johns Hopkins University School of Medicine and his medical oncology fellowship at the National Institutes of Health Clinical Center. He is a 1987 graduate of Case Western Reserve University School of Medicine and also holds an A.B. in Applied Mathematics, Cum Laude, from Harvard University. Currently, Dr. Humphrey is serving as the Chief Executive Officer at RADD Pharmaceuticals.

Education & Training

  • National Institutes of Health Clinical Center
    National Institutes of Health Clinical CenterFellowship, Medical Oncology, 1993 - 1996
  • Johns Hopkins University School of Medicine
    Johns Hopkins University School of MedicineResidency, 1987 - 1990
  • Case Western Reserve University School of Medicine
    Case Western Reserve University School of MedicineClass of 1987
  • Harvard University
    Harvard UniversityA.B., Applied Mathematics, Cum Laude, 1979 - 1983

Certifications & Licensure

  • CT State Medical License
    CT State Medical License 1997 - 2025
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • Best of ASH Presentation American Society of Hematology, 2018
  • Best of ASCO Presentation American Society of Clinical Oncology, 2017
  • Kyowa Hakko Kirin Development Division Top Award Kyowa Hakko Kirin, 2013
  • Join now to see all

Publications & Presentations

PubMed

Journal Articles

  • The BET Inhibitor, CPI-0610, Promotes Myeloid Differentiation in Myelofibrosis Patient Bone Marrow and Peripheral CD34+ Hematopoietic Stem Cells  
    Mertz JA, et al, Blood, 11/5/2020
  • Mogamulizumab versus investigator choice of chemotherapy regimen in relapsed/refractory adult T-cell leukemia/lymphoma: a randomized, phase 2 study.  
    Phillips AA, et. al., Haematologica, 12/20/2018
  • Anti-CCR4 monoclonal antibody mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, randomized, phase 3 trial.  
    Kim YH, et. al., Lancet Oncology, 8/9/2018
  • Join now to see all

Books/Book Chapters

  • Cancer Drug Discovery and Development (book series) 
    Chapter: Maximizing the Therapeutic Potential of Matrix Metalloproteinase Inhibitors for the Treatment of Cancer 
    Page 379 - 390Humphrey JS, et. al.Editors: Hak Choy.Humana Press Inc, Totowa, NJ2003
  • Cancer Treatment and Research 
    Chapter: Von Hippel-Lindau syndrome: hereditary cancer arising from inherited mutations of the VHL tumor suppressor gene 
    Page 13 - 38Humphrey JS, Klausner RD, and Linehan WMEdition 88,1996

Abstracts/Posters

  • Anti-CCR4 Monoclonal Antibody, Mogamulizumab, Demonstrates Significant Improvement in PFS Compared to Vorinostat in Patients with Previously Treated Cutaneous T-Cell L...
    Kim YA, et. al., Blood, 12/7/2017
  • Differences between Japan and rest of world in disease presentation and outcome of previously treated adult t-cell leukemia-lymphoma (ATL) using therapy with a monoclo...
    Phillips AA, et. al., Journal of Clinical Oncology, https://ascopubs.org/doi/10.1200/JCO.2016.34.15_suppl.e19056, 5/20/2016
  • Effect of four monthly doses of a human monoclonal anti-FGF23 antibody (KRN23) on quality of life in X-linked hypophosphatemia.
    Ruppe MD, et. al., Bone Reports, 5/13/2016
  • Join now to see all

Dr. Jeffrey Humphrey, Dr. Jeffrey Humphrey, MD, Dr. J Humphrey, Dr. Jeffrey Steven Humphrey